Skip to contentP
Pulse Biosciences, Inc.
P
PLSEPulse Biosciences, Inc. Q2 2025 · 10-Q
Revenue$0.00$0.00— vs Q2 2024 Net Income-$19.17M-$19.17MN/M vs Q2 2024 EPS, diluted—
Operating Income-$20,275,000N/M Operating Cash Flowderived-$12,807,000N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Pulse Biosciences, Inc. · CIK 1625101 · Engraved from SEC EDGAR
Free Cash Flowderived-$12,910,000N/M ended Jun 30, 2025 · filed Aug 12, 2025 · 43 d after period end